TFA
LCTX icon

Transamerica Financial Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Transamerica Financial Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-5,018
Closed -$17K – 619
2013
Q2 		$17K Buy
+5,018
New +$16.1K ﹤0.01% 372

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Transamerica Financial Advisors's LCTX Position: Q3 2013 in Review

Transamerica Financial Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2013, closing a stake of 5,018 shares — an estimated $17K sold.

Transamerica Financial Advisors first reported a position in LCTX in Q2 2013 and held it in 1 quarter. The position peaked at $17K in Q2 2013. 56 funds tracked by Wall St. Rank hold LCTX as of Q3 2013.

  • Transamerica Financial Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Transamerica Financial Advisors sold 5,018 Lineage Cell Therapeutics shares in Q3 2013, an estimated $17K.
  • Transamerica Financial Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 1 quarter.
  • Transamerica Financial Advisors's Lineage Cell Therapeutics position peaked at $17K in Q2 2013.
  • 56 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2013.

Based on Transamerica Financial Advisors's 13F filing for Q3 2013, filed 22 Oct 2013.